| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a22000007a 4500 |
| 001 |
in00005772091 |
| 005 |
20260327174731.1 |
| 006 |
m o d |
| 007 |
cr un|---aucuu |
| 008 |
230726s2023 xx o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d OPELS
|d UKMGB
|d OCLCF
|d UKAHL
|d UKKRT
|d OCLCL
|d SFB
|
| 015 |
|
|
|a GBC3D2121
|2 bnb
|
| 016 |
7 |
|
|a 021139251
|2 Uk
|
| 020 |
|
|
|a 9780443186127
|q (electronic bk.)
|
| 020 |
|
|
|a 044318612X
|q (electronic bk.)
|
| 020 |
|
|
|z 9780443186110
|
| 035 |
|
|
|a (OCoLC)1391093147
|
| 037 |
|
|
|a 9780443186127
|b Ingram Content Group
|
| 050 |
|
4 |
|a RM301.25
|
| 082 |
0 |
4 |
|a 615.19
|2 23/eng/20230816
|
| 049 |
|
|
|a TXAM
|
| 245 |
0 |
0 |
|a Privileged scaffolds in drug discovery /
|c edited by Bin Yu, Ning Li, Caiyun Fu.
|
| 260 |
|
|
|a [S.l.] :
|b Academic Press,
|c 2023.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Front Cover -- Privileged Scaffolds in Drug Discovery -- Privileged Scaffolds in Drug Discovery -- Copyright -- Contents -- List of contributors -- Preface -- Introduction -- 1 -- Thiazole, a privileged scaffold in drug discovery -- 1. Introduction -- 2. Thiazole derivatives as therapeutic agents -- 2.1 Second-generation cephalosporin antibiotics containing thiazole moiety -- 2.2 Third-generation cephalosporin antibiotics containing thiazole substituent -- 2.3 Aminothiazole-containing third-generation cephalosporins for veterinary use -- 2.4 Cephalosporin antibiotics with aminothiazole group used in prodrug forms -- 2.5 Fourth-generation cephalosporin antibiotics containing thiazole nucleus -- 2.6 Fifth-generation cephalosporin antibiotics and monobactams containing aminothiazole group -- 2.7 Thiazole-containing natural products as antimicrobial agents -- 2.8 Antifungal and antiprotozoal agents containing thiazole nucleus -- 2.9 Thiazole derivatives as antifungal and antituberculosis agents -- 2.10 Thiazole derivatives as anticancer drugs -- 2.11 Thiazole-containing antiproliferative agents -- 2.12 Thiazole-containing drugs to treat inflammatory and blood-borne diseases -- 2.13 Thiazole derivative to treat urologic and neurologic disorders -- 2.14 Miscellaneous drugs and useful compounds containing thiazole nucleus -- 2.15 Thiazole-containing essential bioactive compounds -- 3. Conclusions -- Acknowledgments -- References -- 2 -- Chalcones: Diverse biological activities and structure-activity relationships -- 1. Background -- 2. Biological activities of chalcone derivatives -- 2.1 Anticancer activity -- 2.1.1 Chalcone-azole hybrids -- 2.1.2 Chalcone-furan/thiophene hybrids -- 2.1.3 Chalcone-indole hybrids -- 2.1.4 Chalcone-pyridine hybrids -- 2.2 Antiinflammatory and antioxidant activities -- 2.2.1 Simple chalcone compounds -- 2.2.2 Licochalcone B.
|
| 505 |
8 |
|
|a 2.5 1,2,3-Triazole as bioisostere for other groups -- 3. Biological significance -- 3.1 Anticancer activity -- 3.2 Antimicrobial activity -- 3.3 Other activities -- 4. Conclusions and prospects -- Acknowledgments -- References -- 7 -- Oxazolidinone scaffolds in drug discovery and development -- 1. Introduction -- 2. Launched oxazolidinone antibacterial drugs -- 2.1 Linezolid -- 2.2 Tedizolid -- 3. Modification of linezolid-based oxazolidinone medications -- 3.1 Morpholine ring/C-5 position modifications -- 3.1.1 Morpholine ring modification -- 3.1.2 C-5 modification -- 3.2 Concurrent alterations to C-5 site and morpholine ring -- 3.2.1 Oxazolidinone-biphenyl chalcone hybrid derivative compounds -- 3.2.2 Derivatives of spiropyrimidinetrione oxazolidinone -- 3.2.3 [1,2,5]Triazepane or [1,2,5]oxadiazepane oxazolidinone compounds -- 3.2.4 C-Ring heteroaromatic antibacterial oxazolidinones -- 3.2.5 N-Substituted-glycinyl 1H-1,2,3-triazolyl oxazolidinone derivatives -- 3.2.6 Replaced ligustrazine C-ring oxazolidinone antibiotics -- 3.2.7 Silicon-containing oxazolidinone antibiotics -- 3.2.8 Antibiotic oxazolidinones containing dihydropyridone C-ring unit -- 3.3 Derivatives of tricyclic fused oxazolidinones -- 3.3.1 (Pyridin-3-yl)benzo[1,4]oxazinyl-oxazolidinones -- 3.3.2 (Tetrahydropyridine-4-yl)benzo[1,4]oxazinyl-oxazolidinones -- 3.3.3 Thiomorpholine benzo[1,4]oxazinyl-oxazolidinones -- 3.3.4 Benzo[1,3]oxazinyl-oxazolidinones -- 4. Other novel oxazolidinone derivatives -- 4.1 Azetidinone moieties -- 4.2 Motifs of amide, sulfonamide, and thiourea -- 4.3 Chloroquinoline moieties -- 4.4 Thiazole hybrid moieties -- 4.5 Oxazolidinone derivative-based UDP-3-O-acyl-N-acetylglucosamine deacetylase inhibitor -- 4.6 3-Amino-2-oxazolidinone derivatives -- 5. Effects of oxazolidinone derivatives on other diseases -- 6. Summary and perspective -- References.
|
| 520 |
|
|
|a Privileged Scaffolds in Drug Discovery is the most complete and up-to-date work in the area. Covering a wide range of privileged structures, it is a perfect reference for scientists involved in targeted drug development. The editors recruited experts from several prestigious Chinese institutions to cover the areas of antiviral drugs, chalcone, pyrimidine, (benz)imidazoles, natural product-derived privileged scaffolds, N-Sulfonyl carboxamides, kinase inhibitors, antitumor molecules, antineurodegenerative drugs, triazoles, oxazolidinone, indole and indoline scaffolds, tigliane diterpenoids, peptide and peptide-based drugs, quassinoids, and others including pseudonatural products, macrocycles, stable peptides and peptidomimetics. The book also explores scaffolds in drug molecules approved in recent years. Privileged Scaffolds in Drug Discovery is a complete reference for researchers in drug discovery and organic synthesis, in academic and corporate settings, who are investigating privileged structures upon which to base new drugs. Researchers in medicinal chemistry and chemical biology will also find the contents of this book valuable.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
7 |
|a Drug development.
|2 fast
|0 (OCoLC)fst00898670
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Yu, Bin.
|
| 700 |
1 |
|
|a Li, Ning.
|
| 700 |
1 |
|
|a Fu, Caiyun.
|
| 710 |
2 |
|
|a ScienceDirect (Online service)
|
| 776 |
0 |
8 |
|i ebook version :
|z 9780443186127
|
| 776 |
0 |
8 |
|c Original
|z 0443186111
|z 9780443186110
|w (OCoLC)1366078820
|
| 776 |
0 |
8 |
|i Print version:
|t PRIVILEGED SCAFFOLDS IN DRUG DISCOVERY.
|d [S.l.] : ELSEVIER ACADEMIC PRESS, 2023
|z 0443186111
|w (OCoLC)1366078820
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://www.sciencedirect.com/science/book/9780443186110
|z Connect to the full text of this electronic book
|t 0
|
| 955 |
|
|
|a Elsevier ScienceDirect 2026-2027
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|i 1fe9d599-f05d-4c8d-8c0e-6e9a16539364
|s 08de2d15-9ce7-44db-a122-0716641e7c13
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e RM301.25
|h Library of Congress classification
|
| 998 |
f |
f |
|a RM301.25
|t 0
|l Available Online
|